PfGLURP as LSP (EMVI call 1998)

GLURP (later combined with MSP3 to become GMZ2) remains with Statens Serum Institut
During 2009 EMVI became a separate legal entity in its own right registered in Germany and is now known as European Vaccine Initiative - EEIG.  EMVI, in collaboration with its partners, was successful in 2009 negotiating a five year contract with EDCTP, coordinated by AMANET, for the funding of the project entitled “Fostering Research Capacity, Networking and Project Management through Phase I-IIb Clinical Trials of Candidate Malaria Vaccine GMZ2”. As the title suggests, the project involves Phase II clinical trials of GMZ2 at several African sites. As the mandate of EMVI was primarily to develop experimental malaria vaccines up to Phase II clinical evaluation, GMZ2 will remain with Statens Serum Institut. It is the sincere hope of EVI-EEIG that Statens Serum Institut will be able to commit the resources necessary to continue the highly successful work of EMVI in the development of this promising malaria vaccine candidate, and to make it available to Developing Countries if the EDCTP project is successful.